334 related articles for article (PubMed ID: 1438287)
1. Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Sutter G; Moss B
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10847-51. PubMed ID: 1438287
[TBL] [Abstract][Full Text] [Related]
2. Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genes.
Ludwig H; Mages J; Staib C; Lehmann MH; Lang R; Sutter G
J Virol; 2005 Feb; 79(4):2584-96. PubMed ID: 15681458
[TBL] [Abstract][Full Text] [Related]
3. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Carroll MW; Overwijk WW; Chamberlain RS; Rosenberg SA; Moss B; Restifo NP
Vaccine; 1997 Mar; 15(4):387-94. PubMed ID: 9141209
[TBL] [Abstract][Full Text] [Related]
4. Generation of Recombinant Vaccinia Viruses.
Wyatt LS; Earl PL; Moss B
Curr Protoc Protein Sci; 2017 Aug; 89():5.13.1-5.13.18. PubMed ID: 28762491
[TBL] [Abstract][Full Text] [Related]
5. Selection of recombinant MVA by rescue of the essential D4R gene.
Ricci PS; Schäfer B; Kreil TR; Falkner FG; Holzer GW
Virol J; 2011 Dec; 8():529. PubMed ID: 22152060
[TBL] [Abstract][Full Text] [Related]
6. The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles.
Heljasvaara R; Rodríguez D; Risco C; Carrascosa JL; Esteban M; Rodríguez JR
J Virol; 2001 Jul; 75(13):5778-95. PubMed ID: 11390580
[TBL] [Abstract][Full Text] [Related]
7. Use of recombinant vaccinia virus vectors for cell biology.
Weisz OA; Machamer CE
Methods Cell Biol; 1994; 43 Pt A():137-59. PubMed ID: 7823860
[TBL] [Abstract][Full Text] [Related]
8. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons.
Geller AI; Breakefield XO
Science; 1988 Sep; 241(4873):1667-9. PubMed ID: 2843986
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia Virus Gene Acquisition through Nonhomologous Recombination.
Vallée G; Norris P; Paszkowski P; Noyce RS; Evans DH
J Virol; 2021 Jun; 95(14):e0031821. PubMed ID: 33910949
[TBL] [Abstract][Full Text] [Related]
10. Preparation of cell cultures and vaccinia virus stocks.
Earl PL; Cooper N; Wyatt LS; Moss B; Carroll MW
Curr Protoc Protein Sci; 2001 May; Chapter 5():Unit5.12. PubMed ID: 18429178
[TBL] [Abstract][Full Text] [Related]
11. Generation of Recombinant Vaccinia Viruses.
Wyatt LS; Earl PL; Moss B
Curr Protoc Microbiol; 2015 Nov; 39():14A.4.1-14A.4.18. PubMed ID: 26528782
[TBL] [Abstract][Full Text] [Related]
12. Generation of recombinant vaccinia virus and analysis of virus-induced cell death.
Liu Z; Kang K; Ka-Ming Chan F
STAR Protoc; 2021 Dec; 2(4):100871. PubMed ID: 34661172
[TBL] [Abstract][Full Text] [Related]
13. Low-resolution structure of vaccinia virus DNA replication machinery.
Sèle C; Gabel F; Gutsche I; Ivanov I; Burmeister WP; Iseni F; Tarbouriech N
J Virol; 2013 Feb; 87(3):1679-89. PubMed ID: 23175373
[TBL] [Abstract][Full Text] [Related]
14. Growth and Purification of Vaccinia Virus Stocks for MPM Imaging.
Reynoso GV; Shannon JP; Americo JL; Gibbs J; Hickman HD
Methods Mol Biol; 2019; 2023():287-299. PubMed ID: 31240685
[TBL] [Abstract][Full Text] [Related]
15. The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis.
Bella Á; Melero I; Berraondo P; Aranda F
Oncoimmunology; 2023; 12(1):2285106. PubMed ID: 38126032
[TBL] [Abstract][Full Text] [Related]
16. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.
Tapia MD; Sow SO; Lyke KE; Haidara FC; Diallo F; Doumbia M; Traore A; Coulibaly F; Kodio M; Onwuchekwa U; Sztein MB; Wahid R; Campbell JD; Kieny MP; Moorthy V; Imoukhuede EB; Rampling T; Roman F; De Ryck I; Bellamy AR; Dally L; Mbaya OT; Ploquin A; Zhou Y; Stanley DA; Bailer R; Koup RA; Roederer M; Ledgerwood J; Hill AVS; Ballou WR; Sullivan N; Graham B; Levine MM
Lancet Infect Dis; 2016 Jan; 16(1):31-42. PubMed ID: 26546548
[TBL] [Abstract][Full Text] [Related]
17. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].
Mayr A; Stickl H; Müller HK; Danner K; Singer H
Zentralbl Bakteriol B; 1978 Dec; 167(5-6):375-90. PubMed ID: 219640
[TBL] [Abstract][Full Text] [Related]
18. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.
Altenburg AF; Kreijtz JH; de Vries RD; Song F; Fux R; Rimmelzwaan GF; Sutter G; Volz A
Viruses; 2014 Jul; 6(7):2735-61. PubMed ID: 25036462
[TBL] [Abstract][Full Text] [Related]
19. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Volz A; Sutter G
Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
[TBL] [Abstract][Full Text] [Related]
20. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.
Meyer H; Sutter G; Mayr A
J Gen Virol; 1991 May; 72 ( Pt 5)():1031-8. PubMed ID: 2033387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
